[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-327034-105":59,"doc-detail-327034-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-of-patients-with-anal-cancer-treated-with-definitive-chemoradiation-a-single-centre-experience","Outcomes of patients with anal cancer treated with definitive chemoradiation - A single centre experience","","Anal cancers are rare neoplasms, and concurrent chemoradiation is the standard therapy for non-metastatic anal squamous cell carcinoma. A cross-sectional review assessed response rates and 2-year survival after definitive chemoradiation in non-metastatic ASCC patients treated at a single institute over the last 10 years. Seventeen eligible patients were included, with radiologic response documented in 16. Results showed over 80% complete radiological response, more than two-thirds 2-year disease-free survival, and about 20% recurrence. The review highlights treatment impact and local incidence patterns in Pakistan.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-of-patients-with-anal-cancer-treated-with-definitive-chemoradiation-a-single-centre-experience/327034/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-of-patients-with-anal-cancer-treated-with-definitive-chemoradiation-a-single-centre-experience/327034.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment approach was evaluated in this study?","Question",{"text":112,"@type":113},"The study evaluated definitive chemoradiation for patients with non-metastatic anal squamous cell carcinoma (ASCC). Treatment response and survival outcomes were assessed after completion of therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were treatment responses documented and defined?",{"text":117,"@type":113},"Responses were documented using contrast-enhanced MRI or CT at defined time points. Complete response, partial response, no response, and progressive disease were categorized based on radiographic criteria described in the methods.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcome findings for survival and recurrence?",{"text":121,"@type":113},"More than 80% of patients showed complete radiological response, and among survivors the 2-year disease-free survival rate was over two-thirds. Approximately 20% experienced disease recurrence during follow-up clinic visits after treatment completion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},327034,1790658449,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience  \nMirza Rameez Samar1, Bakhtawar Masood1, Nida E Zehra1, Tahir Munir2, Misbah Younus Soomro1, Muhammad Arif Hameed1, Insia Ali1 and Yasmin Abdul Rashid1  \n1Department of Oncology, The Aga Khan University, Karachi 74600, Pakistan  \n2Department of Anaesthesia, The Aga Khan University, Karachi 74600, Pakistan  \nAbstract  \nBackground: Anal cancers are uncommon neoplasms that make up to \u003C1% of all tumours globally. Concurrent chemoradiation remains the standard of care treatment for patients who present with non-metastatic anal squamous cell carcinomas (ASCCs) .  \nMethods: We aimed to evaluate the response rate and 2-year survival outcome of the definitive chemoradiation approach in patients with non-metastatic ASCCs of our population. We conducted a cross-sectional review of these patient populations who were treated and then followed after completion of treatment at our institute during the last 10 years.  \nResults: A total of 17 patients were enrolled after fulfillment of the eligibility criteria. The responses were documented in 16 patients through magnetic resonance imaging or computed tomography of the pelvis, done at 3 months of treatment completion. More than 80% of the patients had complete radiological responses. Among the surviving participants, the 2-year disease-free survival rate was found to be more than two-thirds. Approximately 20% of the study participants had disease recurrence during the subsequent clinic visits following treatment completion.  \nConclusion: This review emphasises the impact of definitive chemo-radiation in achieving radiological and clinical responses in patients with non-metastatic ASCCs. Moreover, to our knowledge, this is the first review to highlight anal cancer’s incidence and characteristics in Pakistan.  \nKeywords: anal cancer, definitive chemoradiation, squamous cell carcinoma, non-metastatic, disease-free survival  \nBackground  \nNeoplasms arising from the anal canal are referred to as anal cancers. They comprise \u003C1% of all cancer cases diagnosed in the United States. In Pakistan, they give rise to approximately 0.23% of all the cancers diagnosed in our country [1] . Among the various subtypes, anal squamous cell carcinoma (ASCC) is the predominant subtype, constituting  \nCorrespondence to: Mirza Rameez Samar  \nEmail: [rameez_samar_1992@hotmail.com](rameez_samar_1992@hotmail.com)  \necancer 2024, 18:1655  \n[https://doi.org/10.3332/ecancer.2024.1655](https://doi.org/10.3332/ecancer.2024.1655)  \nPublished: 15/01/2024  \nReceived: 16/11/2023  \nPublication costs for this article were supported byecancer (UK Charity number 1176307) .  \nCopyright: © the authors; licenseeecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ([http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0](creativecommons.org/licenses/by/4.0)), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \necancer 2024, 18:1655; [www.ecancer.org](www.ecancer.org); DOI: [https://doi.org/10.3332/ecancer.2024.1655](https://doi.org/10.3332/ecancer.2024.1655) 1  \nResearch  \nup to >80% of all anal cancer cases. The state-of-the-art treatment of non-metastatic ASCC is a non-surgical, multimodal approach of chemo-radiotherapy (CRT) i.e., radiotherapy given with chemotherapeutic agents as radio-sensitisers. The current CRT approach involves 5-fluorouracil (5FU) and mitomycin C with radiotherapy, which provides a local disease control rate of 59% at 42 months when compared to 36% with radiotherapy alone [2] .  \nIn this study, we aim to determine the response rates, 2-year disease-free survival (DFS), and patterns of recurrence from a combined CRT approach in patients with non-metastatic anal cancer presenting at a tertiary care institute in Pakistan.  \nMethods  \nWe conducted a retrospe","cbCaiaUsjU5IPe3x","https://ap.wps.com/l/cbCaiaUsjU5IPe3x","pdf",321291,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n# Research\n# Methods","[{\"question\":\"What treatment approach was evaluated in this study?\",\"answer\":\"The study evaluated definitive chemoradiation for patients with non-metastatic anal squamous cell carcinoma (ASCC). Treatment response and survival outcomes were assessed after completion of therapy.\"},{\"question\":\"How were treatment responses documented and defined?\",\"answer\":\"Responses were documented using contrast-enhanced MRI or CT at defined time points. Complete response, partial response, no response, and progressive disease were categorized based on radiographic criteria described in the methods.\"},{\"question\":\"What were the main outcome findings for survival and recurrence?\",\"answer\":\"More than 80% of patients showed complete radiological response, and among survivors the 2-year disease-free survival rate was over two-thirds. Approximately 20% experienced disease recurrence during follow-up clinic visits after treatment completion.\"}]","Outcomes of patients with anal cancer treated with definitive chemoradiation - A single centre experience | PDF",1789976014,25]